Daniel Barber - 09 Mar 2026 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Role
President and CEO
Signature
/s/ Lori Braender, as Attorney-In-Fact
Issuer symbol
AQST
Transactions as of
09 Mar 2026
Net transactions value
-$753,965
Form type
4
Filing time
11 Mar 2026, 12:52:40 UTC
Previous filing
29 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Barber Daniel President and CEO C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN /s/ Lori Braender, as Attorney-In-Fact 11 Mar 2026 0001742266

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AQST Common Stock Award +262,000 +28% $0.000000* 1,185,430 09 Mar 2026 Direct F1
transaction AQST Common Stock Sale $753,965 -180,677 -15% $4.17 1,004,753 10 Mar 2026 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AQST Non-Qualified Stock Option (right to buy) Award +523,000 $4.29* 523,000 09 Mar 2026 Common Stock 523,000 $4.29 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
F2 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3 This transaction was executed in multiple trades at prices ranging from $4.17 to $4.33. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.